Vetchý D, Frýbortová K, Rabisková M, Danecková H
Usta technologie léků, Farmaceutická fakulta, Veterinárni a farmaceutická univerzita, Brno.
Cas Lek Cesk. 2007;146(5):431-3.
Bioequivalence studies are very important for the development of a pharmaceutical preparation in the pharmaceutical industry. Their rationale is the monitoring of pharmacokinetic and pharmacodynamic parameters after the administration of tested drugs. The target of such study is to evaluate the therapeutic compatibility of tested drugs (pharmaceutical equivalents or pharmaceutical alternatives). The importance of bioequivalence studies is increasing also due to the large growth of the production and consumption of generic products. Generic products represent approximately 50 % of the whole consumption in many European countries and USA. The search output of bioequivalence study is together with the pharmaceutical quality data of medical product one of the main part of the registration file submitted to a national regulatory authorities. The registration of generic products does not demand complicated and expensive clinical study contrary to original product. The comparison of the original and the generic product via bioequivalence study is suggested as sufficient. The aim of this article is to provide to a medical public a summary about the types of bioequivalence studies, their range, rules of their practise and let them gain their own attitude to this question.
生物等效性研究对于制药行业中药物制剂的开发非常重要。其基本原理是监测受试药物给药后的药代动力学和药效学参数。此类研究的目标是评估受试药物(药学等效物或药学替代物)的治疗等效性。由于仿制药生产和消费的大幅增长,生物等效性研究的重要性也在不断提高。在许多欧洲国家和美国,仿制药约占总消费量的50%。生物等效性研究的结果与药品的药学质量数据一起,是提交给国家监管机构的注册文件的主要组成部分之一。与原研产品不同,仿制药的注册不需要复杂且昂贵的临床研究。通过生物等效性研究对原研产品和仿制药进行比较被认为是足够的。本文的目的是向医学界人士提供有关生物等效性研究类型、范围、实施规则的概述,并让他们对这个问题形成自己的看法。